Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Bitopertin · DISC-1459, RO4917838

Small molecule · developed by Disc Medicine

Phase 2/3 Most advanced trial
IRON Developer
1 Registered trials

What is Bitopertin?

Bitopertin (also known as DISC-1459, RO4917838, R-1678 and RG-1678) is a small molecule studied in erythropoietic protoporphyria, an inherited disorder of heme biosynthesis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
DISC-1459, RO4917838, R-1678, RG-1678
Drug type
Small molecule
Therapy area
Dermatology, Gastroenterology, Metabolic
Developer
Disc Medicine, Inc (IRON)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
Q8L6AN59YY

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05883748 Phase 2/3 Erythropoietic Protoporphyria Enrolling by invitation IRON

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Erythropoietic Protoporphyria

More from Disc Medicine

Follow IRON, the company behind Bitopertin

See IRON's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IRON catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.